- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00041041
Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
A Phase II Evaluation Of Gleevec (Imatinib Mesylate) (IND #61135, NSC #716051) In The Treatment Of Persistent Or Recurrent Epithelial Ovarian Or Primary Peritoneal Carcinoma
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To evaluate the cytostatic, anti-tumor activity of Gleevec (Imatinib Mesylate) through the probability of surviving progression-free for at least 6 months in patients with recurrent or persistent epithelial ovarian or primary peritoneal carcinoma receiving Gleevec.
II. To determine the frequency and severity of adverse effects of Gleevec in this cohort of patients as assessed by CTC.
SECONDARY OBJECTIVES:
I. To determine the distribution of the overall survival. II. To determine the distribution of progression-free survival. III. To estimate the clinical response rate (partial and complete response as defined under the RECIST criteria).
IV. To assess the effects of prognostic variables: initial performance status, platinum sensitivity, and mucinous (or clear cell) histology).
TERTIARY OBJECTIVES:
I. To determine the levels of expression of c-KIT and its ligand, stem cell factor (SCF) in archived, formalin fixed, paraffin embedded primary tumors collected prior to the initiation of first-line chemotherapy.
II. To determine the levels of expression of platelet derived growth factor receptor (PDGFR) and its ligand PDGF in archived, formalin fixed, paraffin embedded primary tumors collected prior to the initiation of first-line chemotherapy.
III. To determine the levels of expression of AKT2 and its activated form, phospho-AKT2, in archived, formalin fixed, paraffin embedded primary tumors collected prior to the initiation of first-line chemotherapy.
OUTLINE: This is a multicenter study.
Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19103
- Gynecologic Oncology Group
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Histologically confirmed ovarian epithelial or primary peritoneal carcinoma
- Recurrent or persistent disease
At least 1 unidimensionally measurable target lesion
- At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
- Tumors within a previously irradiated field considered nontarget lesions
At least one prior platinum-based chemotherapy regimen (containing carboplatin, cisplatin, or another organoplatinum compound) for primary disease required
- Initial treatment may include high-dose, consolidation, or extended therapy
- Initial treatment-free interval less than 12 months for patients who received only 1 prior platinum-based regimen
- Initial treatment-free interval of more than 12 months allowed provided disease progression has occurred within 12 months after retreatment with a second-line platinum-based regimen
- Ineligible for a higher priority GOG protocol (e.g., any active phase III GOG protocol for the same patient population)
- Performance status - GOG 0-2 (if patient has received one prior treatment regimen)
- Performance status - GOG 0-1 (if patient has received two prior treatment regimens)
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- SGOT/SGPT no greater than 2.5 times ULN
- Alkaline phosphatase no greater than 2.5 times ULN
- Creatinine no greater than 1.5 times ULN
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier contraception during and for 3 months after study participation
- No active infection requiring antibiotics
- No greater than grade 1 sensory and motor neuropathy
- No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
- No signs or symptoms of bowel dysfunction
- At least 3 weeks since prior immunologic therapy directed at the malignant tumor
- No concurrent biologic therapy or immunotherapy for the malignant tumor
- Recovered from prior chemotherapy
- No prior noncytotoxic chemotherapy for persistent or recurrent disease
- One additional cytotoxic regimen for persistent or recurrent disease allowed
- No concurrent chemotherapy for the malignant tumor
- At least 1 week since prior hormonal therapy directed at the malignant tumor
- No concurrent therapeutic corticosteroids
- No concurrent anticancer hormonal therapy
- Concurrent hormone replacement therapy allowed
- Recovered from prior radiotherapy
- No prior radiotherapy to more than 25% of marrow-bearing areas
- No concurrent anticancer radiotherapy
- Recovered from recent prior surgery
- At least 3 weeks since other prior therapies directed at the malignant tumor
- No prior imatinib mesylate
- No prior anticancer therapy that would preclude study participation
- No concurrent therapeutic anticoagulation with warfarin
- No other concurrent investigational drugs
- No concurrent amifostine or other protective reagents
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Treatment (imatinib mesylate)
Patients receive oral imatinib mesylate twice daily on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Korrelative Studien
PO gegeben
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Progressionsfreies Überleben
Zeitfenster: Mit 6 Monaten
|
Mit 6 Monaten
|
Häufigkeit und Schweregrad von Nebenwirkungen gemäß CTC-Bewertung
Zeitfenster: Bis zu 7 Jahre
|
Bis zu 7 Jahre
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Dauer des progressionsfreien Überlebens
Zeitfenster: Bis zu 7 Jahre
|
Bis zu 7 Jahre
|
Dauer des Gesamtüberlebens
Zeitfenster: Bis zu 7 Jahre
|
Bis zu 7 Jahre
|
Häufigkeit des klinischen Ansprechens (partielles und vollständiges Ansprechen)
Zeitfenster: Bis zu 7 Jahre
|
Bis zu 7 Jahre
|
Prognostic variables: initial performance status, age, platinum sensitivity, and mucinous (or clear cell) histology
Zeitfenster: Baseline
|
Baseline
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen nach histologischem Typ
- Neubildungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Karzinom
- Neubildungen, Drüsen und Epithelien
- Genitale Neubildungen, weiblich
- Erkrankungen des endokrinen Systems
- Krankheitsattribute
- Eierstockerkrankungen
- Adnexerkrankungen
- Gonadenstörungen
- Neoplasmen der endokrinen Drüse
- Eierstocktumoren
- Wiederauftreten
- Karzinom, Eierstockepithel
- Molekulare Mechanismen der pharmakologischen Wirkung
- Enzym-Inhibitoren
- Antineoplastische Mittel
- Proteinkinase-Inhibitoren
- Imatinibmesylat
Andere Studien-ID-Nummern
- NCI-2012-02473
- U10CA027469 (US NIH Stipendium/Vertrag)
- GOG-0170E
- CDR0000069438 (Registrierungskennung: PDQ (Physician Data Query))
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Labor-Biomarker-Analyse
-
Vanderbilt University Medical Center4DMedicalAbgeschlossen
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Noch keine RekrutierungHIV-Infektionen | Hepatitis B
-
Duke UniversityZurückgezogenAntikoagulations- und Thrombose-Point-of-Care-Test (AT-POCT)Vereinigte Staaten
-
Columbia UniversityAbgeschlossen
-
McGill University Health Centre/Research Institute...Northwestern UniversityRekrutierungApnoe der FrühgeburtlichkeitKanada
-
Emory UniversityDermatology FoundationBeendetKutaner Lupus erythematodesVereinigte Staaten